Wire · operational-macro
Nvidia-backed Iambic Therapeutics launches IPO as biotechs buck market gloom
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 9 October 2026 · Fusion42 review
Iambic Therapeutics, using AI to develop drugs for solid tumors, is aiming to raise $159.4 million in a US IPO valuing the company up to $805.8 million amid strong investor interest in AI-enhanced biotech. The IPO highlights biotech as a resilient sector against broader market volatility and geopolitical tensions, with major pharma partnerships and AI-driven drug discovery fueling growth.
This Wire brief sits within Fusion42's coverage of Biotech, and 2 sources have reported it between 8 Oct 2026 and 15 Oct 2026.
◆ ◆ The Wire takeaway
AI-driven biotech is proving a strong draw for investors despite market turbulence, so if you develop drug discovery tech or partner with pharma, now is a rare moment to push market entry and fundraising.
◆ Coverage
2 sources · first reported 8 Oct 2026 · latest 15 Oct 2026
◆ Related on Wire
◆ Topics